
Every big bank app is down Prior auth portal unaffected: still pending
✓Chair, Radiation Oncology, University of Vermont Health

Every big bank app is down Prior auth portal unaffected: still pending

Outlook down Thurs, every US flight grounded Fri, linac on time at 7am #radonc

Outlook down since 1 PM, expected “impacted” through the night Tomorrow's inbox: 300 emails, 3 that matter, and 40 reply-alls asking if anyone else's Outlook is down

Target-trial emulation is still observational research. Treatment selection isn't random. Same core concern as other observational comparisons: unmeasured confounding, particularly confounding by indication. Better design helps, but doesn't replace randomization.


Honored to be elected to the @nnecos_oncology Board. NNECOS brings together oncology across ME, NH, and VT & gives our trainees a real regional stage. Looking forward to the work ahead with colleagues across the region.

ENZARAD @JCO | ANZUP 1303 n=802 | mFU 92 mo ADT+RT ± enza 24 mo vs NSAA 6 mo MFS/OS overall ⛔️ pelvic RT subgroup 🎯 HR 0.47 no Decipher/PAM50 - still unclear who benefits from intensification ascopubs.org/doi/10.1200/JCO…

#ESMO26 @niazi_Dr7 DASL-HiCaP (ANZUP1801) n=1,106 | mFU 3.8 yrs | 85% definitive RT darolutamide + ADT + RT v placebo + ADT + RT MFS-CI ➡️ HR 0.42 (0.27–0.66) 4-yr MFS 95% vs 88%


At #ASTRO26, we are proud to welcome so many Yale attendees, including our current residents and the alumni of our Radiation Oncology Residency Program @YaleRadOnc, all representing @YaleMed @SmilowCancer @YNHH and advancing the field of radiation oncology. @ASTRO_org @OncoAlert

Back in 🇬🇧 but still able to listen to @nickva1 presenting @ASTRO_org #ASTRO26 @royalmarsdenNHS @EmmaHall71 No surprises here, patients have better sexual outcomes after SBRT compared to prostatectomy

Grateful to organizers for PRO 11 @ #ASTRO26: Trial design keeps getting more complicated. Ph II data, de-escalation/omission studies, new tech routinely reported as practice-changing. Outstanding talks on how to read that evidence and which results should change practice!

#ASTRO26 climate change, IT risk, and other system shocks make this more relevant every year. The real value here was in the stories: lessons for prevention and prep, and what we can actually do to safeguard RT when the next disruption hits. Thank you to this panel!

Long-term PACE-A data at #ASTRO26 (van As LBA32, Yasar LBA10): the first randomized comparison of prostatectomy vs SBRT, 36.25 Gy in 5 fractions. These are contemporary surgical data: all prostatectomies were laparoscopic, 84% robotic. Using ≥1 pad/day, RP vs SBRT: • 2 years: 50% vs 7% • 5 years: 48% vs 8% Sexual function at 5 years: • EPIC sexual domain: 62→17 after RP vs 79→58 after SBRT • Median IIEF-5: 5 vs 19 Important caveats: as-treated analysis, approximately 60% PRO completion at 5 years, baseline sexual function imbalance, and enrollment of 123 of a planned 234 patients. Biochemical control looks similar through 8 years, but 13 events cannot establish equivalence. For shared decision-making, these are numbers I’d want patients to see. Every patient considering prostatectomy should have the opportunity to meet with a radiation oncologist before choosing treatment. #RadOnc #PCSM

